A secondary analysis from the SWOG S0931 EVEREST trial has found that in the subgroup of patients with clear-cell renal cell carcinoma (RCC) who were at very-high risk of recurrence, those who were treated with everolimus after surgery had a statistically significant improvement in recurrence-free survival compared to patients getting placebo...
Reviewed by Danielle Ellis, B.Sc.Oct 22 2023 A secondary analysis from the SWOG S0931 EVEREST trial has found that in the subgroup of patients with clear-cell renal cell carcinoma who were at very-high risk of recurrence, those who were treated with everolimus after surgery had a statistically significant improvement in recurrence-free survival compared to patients getting placebo after surgery.
The trial's primary results, published earlier this year in The Lancet by a team led by S0931 principal investigator Christopher W. Ryan, MD, of Oregon Health and Science University Knight Cancer Institute, found that although recurrence-free survival time was longer for patients on the everolimus arm, the difference narrowly missed meeting the criterion for statistical significance.
Importantly, the characteristics of patients in this subgroup – patients with RCC with a clear-cell component whose disease was completely resected and who were considered at very high risk for recurrence – closely resemble those of the patients enrolled to the only two previous clinical trials of adjuvant therapy in RCC that reported positive results. These trials were the S-TRAC and KN546 studies, each of which led to Food and Drug Administration approval of a drug.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Highest risk patients with clear-cell renal cell carcinoma benefit from adjuvant everolimus: Clinical trialA secondary analysis from the SWOG S0931 EVEREST trial has found that in the subgroup of patients with clear-cell renal cell carcinoma (RCC) who were at very-high risk of recurrence, those who were treated with everolimus after surgery had a statistically significant improvement in recurrence-free survival compared to patients getting placebo...
続きを読む »
Belzutifan outperforms everolimus in advanced kidney cancer treatmentBelzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, in patients previously treated with immune checkpoint inhibitors and anti-angiogenic therapies compared with everolimus in a phase 3 clinical trial. The trial, led by Toni K.
続きを読む »
Bagnaia: “Was clear to me that soft tyre would have this type of drop”Francesco Bagnaia says MotoGP title rival Jorge Martin was the only rider that could make the soft rear tyre last for a full race, but that the drop he suffered was no surprise.
続きを読む »
Liverpool change script as Everton players make anger clear behind the scenesVerdict from Paul Gorst after Liverpool beat Everton 2-0 in the Merseyside derby
続きを読む »
Jurgen Klopp solves problem position as Virgil van Dijk best partner clearAnalysis from Ian Doyle after Liverpool beat Everton 2-0 at Anfield in the 243rd Merseyside derby thanks to a brace of late goals from Mohamed Salah
続きを読む »
Diggerss move in to clear former golf course as work on housing estate beginsAfter a planning sage lasting years the new estate is being built at the Horwich golf club site
続きを読む »